Mahdi Behi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahdi Behi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Babak Gholamine
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ramin Haghighi
Department of Urology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran
2 shared publications - Ahmad Maleki Ahmadabadi
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication - Ali Karimi Bakhshandi
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
1 shared publication - Ali Rahnama Sisakht
General Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication - Alireza Habibzadeh
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication
Latest Publications
- Open Access
- 7 July 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14 (4) , e27643
The visceral adiposity index as a predictor of chronic kidney disease; a systematic review and meta-analysis
Introduction: Visceral fat accumulation and insulin resistance play significant roles in the pathogenesis of chronic kidney disease (CKD). Objectives: This study aimed to assess the association between the visceral adiposity index (VAI) and CKD using a systematic review and meta-analysis method. Materials and Methods: The sources were searched in the Web of Science, Cochrane, PubMed, Embase, and Scopus databases, as well as the Google Scholar search engine. Data were analyzed using STATA 14 at a significance level of P < 0.05. Results: The results obtained from a combination of 21 observational studies revealed that CKD risk increased with high VAI values in total subjects (OR: 1.12, 95% CI: 1.08, 1.16), men (OR: 1.14, 95% CI: 1.07, 1.22), and women (OR: 1.22, 95% CI: 1.13, 1.32), as well as in cross-sectional (OR: 1.12, 95% CI: 1.07, 1.17) and cohort (OR: 1.17, 95% CI: 1.07, 1.29) studies. In addition, high VAI values elevated CKD risk in Taiwan (OR: 1.50, 95% CI: 1.08, 2.08), Turkey (OR: 1.47, 95% CI: 1.02, 2.10), China (OR: 1.35, 95% CI: 1.14, 1.60), Cameroon (OR: 1.13, 95% CI: 1.05, 1.22), and the USA (OR: 1.05, 95% CI: 1.03, 1.07). Conclusion: The risk of CKD rose with high VAI values in all participants (12%), with a higher rate in women (22%) than in men (14%). Moreover, the highest and least risks were reported in Taiwanese and USA patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251037963) and Research Registry (UIN: reviewregistry1984) websites.
- 7 July 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14 (4) , e27643
Open AccessThe visceral adiposity index as a predictor of chronic kidney disease; a systematic review and meta-analysis
Introduction: Visceral fat accumulation and insulin resistance play significant roles in the pathogenesis of chronic kidney disease (CKD). Objectives: This study aimed to assess the association between the visceral adiposity index (VAI) and CKD using a systematic review and meta-analysis method. Materials and Methods: The sources were searched in the Web of Science, Cochrane, PubMed, Embase, and Scopus databases, as well as the Google Scholar search engine. Data were analyzed using STATA 14 at a significance level of P < 0.05. Results: The results obtained from a combination of 21 observational studies revealed that CKD risk increased with high VAI values in total subjects (OR: 1.12, 95% CI: 1.08, 1.16), men (OR: 1.14, 95% CI: 1.07, 1.22), and women (OR: 1.22, 95% CI: 1.13, 1.32), as well as in cross-sectional (OR: 1.12, 95% CI: 1.07, 1.17) and cohort (OR: 1.17, 95% CI: 1.07, 1.29) studies. In addition, high VAI values elevated CKD risk in Taiwan (OR: 1.50, 95% CI: 1.08, 2.08), Turkey (OR: 1.47, 95% CI: 1.02, 2.10), China (OR: 1.35, 95% CI: 1.14, 1.60), Cameroon (OR: 1.13, 95% CI: 1.05, 1.22), and the USA (OR: 1.05, 95% CI: 1.03, 1.07). Conclusion: The risk of CKD rose with high VAI values in all participants (12%), with a higher rate in women (22%) than in men (14%). Moreover, the highest and least risks were reported in Taiwanese and USA patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251037963) and Research Registry (UIN: reviewregistry1984) websites.
- 12 March 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-10
Therapeutic potential of microbiota modulation in psoriasis: current evidence and future directions
The human microbiota plays a significant role in health and the development of autoimmune diseases by maintaining gut-skin homeostasis through diverse microbial communities. Dysbiosis, or imbalance in these communities, is increasingly recognized as a contributing factor in the pathogenesis of autoimmune and inflammatory diseases, including psoriasis. Psoriasis is characterized by immune dysregulation, leading to red and scaly plaques that significantly reduce patients’ quality of life. Current evidence highlights the gut microbiota's critical role in driving immune responses and chronic inflammation associated with psoriasis. Therapeutic strategies aimed at restoring microbial balance, such as probiotics, have demonstrated promise in reducing disease severity. Additionally, fecal microbiota transplantation (FMT) has emerged as a novel intervention, with early studies suggesting its potential to alleviate symptoms by correcting gut dysbiosis. These approaches underscore the importance of microbiota-targeted therapies in addressing the systemic nature of psoriasis and pave the way for advancements in personalized treatment strategies.
- 12 March 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-10
Therapeutic potential of microbiota modulation in psoriasis: current evidence and future directions
The human microbiota plays a significant role in health and the development of autoimmune diseases by maintaining gut-skin homeostasis through diverse microbial communities. Dysbiosis, or imbalance in these communities, is increasingly recognized as a contributing factor in the pathogenesis of autoimmune and inflammatory diseases, including psoriasis. Psoriasis is characterized by immune dysregulation, leading to red and scaly plaques that significantly reduce patients’ quality of life. Current evidence highlights the gut microbiota's critical role in driving immune responses and chronic inflammation associated with psoriasis. Therapeutic strategies aimed at restoring microbial balance, such as probiotics, have demonstrated promise in reducing disease severity. Additionally, fecal microbiota transplantation (FMT) has emerged as a novel intervention, with early studies suggesting its potential to alleviate symptoms by correcting gut dysbiosis. These approaches underscore the importance of microbiota-targeted therapies in addressing the systemic nature of psoriasis and pave the way for advancements in personalized treatment strategies.
- Open Access
- 25 May 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
The effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the antidiabetic drugs with unclear relationship effect on kidney stones. Accordingly, this study aimed to investigate the relationship between SGLT2 inhibitors treatment and kidney calculi incidence using systematic review and meta-analysis. Materials and Methods: The PRISMA statement was used to write this systematic review and meta-analysis. Databases, including ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar, were used to access the resources without a lower time limit until November 5, 2023. Data analysis was conducted using STATA 14 software. Results: Results obtained from six studies with a total of 4963542 participants indicated that SGLT2 inhibitors administration reduced the possibility of kidney calculi in general (OR = 0.80, 95% CI: 0.72, 0.89), in men (OR = 0.92, 95% CI: 0.86, 0.98), and women (OR = 0.93, 95% CI: 0.89, 0.97). SGLT2 inhibitors treatment prevented kidney calculi in cross-sectional studies (OR = 0.92, 95% CI: 0.89, 0.96), cohort studies (OR = 0.71, 95% CI: 0.66, 0.77), RCT study (OR = 0.64, 95% CI: 0.48, 0.86), Japan (OR = 0.92, 95% CI: 0.89, 0.96), United States (OR = 0.72, 95% CI: 0.67, 0.76), Denmark (OR = 0.51, 95% CI: 0.37, 0.71), compared with DPP4i (OR = 0.74, 95% CI: 0.71, 0.77), compared with GLP1RA (OR = 0.62, 95% CI: 0.47, 0.82), compared with other antidiabetic drugs (OR = 0.92, 95% CI: 0.89, 0.96), and compared with placebo (OR = 0.64, 95% CI: 0.48, 0.86). Conclusion: Compared with placebo and other antidiabetic drugs, SGLT2 inhibitors reduce the risk of kidney calculi. However, considering the limited number of investigated studies, more studies in this field are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023483132) and Research Registry (UIN: reviewregistry1743) websites.
- 25 May 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessThe effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the antidiabetic drugs with unclear relationship effect on kidney stones. Accordingly, this study aimed to investigate the relationship between SGLT2 inhibitors treatment and kidney calculi incidence using systematic review and meta-analysis. Materials and Methods: The PRISMA statement was used to write this systematic review and meta-analysis. Databases, including ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar, were used to access the resources without a lower time limit until November 5, 2023. Data analysis was conducted using STATA 14 software. Results: Results obtained from six studies with a total of 4963542 participants indicated that SGLT2 inhibitors administration reduced the possibility of kidney calculi in general (OR = 0.80, 95% CI: 0.72, 0.89), in men (OR = 0.92, 95% CI: 0.86, 0.98), and women (OR = 0.93, 95% CI: 0.89, 0.97). SGLT2 inhibitors treatment prevented kidney calculi in cross-sectional studies (OR = 0.92, 95% CI: 0.89, 0.96), cohort studies (OR = 0.71, 95% CI: 0.66, 0.77), RCT study (OR = 0.64, 95% CI: 0.48, 0.86), Japan (OR = 0.92, 95% CI: 0.89, 0.96), United States (OR = 0.72, 95% CI: 0.67, 0.76), Denmark (OR = 0.51, 95% CI: 0.37, 0.71), compared with DPP4i (OR = 0.74, 95% CI: 0.71, 0.77), compared with GLP1RA (OR = 0.62, 95% CI: 0.47, 0.82), compared with other antidiabetic drugs (OR = 0.92, 95% CI: 0.89, 0.96), and compared with placebo (OR = 0.64, 95% CI: 0.48, 0.86). Conclusion: Compared with placebo and other antidiabetic drugs, SGLT2 inhibitors reduce the risk of kidney calculi. However, considering the limited number of investigated studies, more studies in this field are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023483132) and Research Registry (UIN: reviewregistry1743) websites.
- Open Access
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Open AccessInvestigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites